CN107865968B - 用于治疗溶酶体贮积症的环糊精 - Google Patents

用于治疗溶酶体贮积症的环糊精 Download PDF

Info

Publication number
CN107865968B
CN107865968B CN201711057517.4A CN201711057517A CN107865968B CN 107865968 B CN107865968 B CN 107865968B CN 201711057517 A CN201711057517 A CN 201711057517A CN 107865968 B CN107865968 B CN 107865968B
Authority
CN
China
Prior art keywords
cyclodextrin
tocopherol
delta
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201711057517.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107865968A (zh
Inventor
J·麦丘
W·郑
M·许
M·斯瓦鲁普
J·J·马鲁甘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN107865968A publication Critical patent/CN107865968A/zh
Application granted granted Critical
Publication of CN107865968B publication Critical patent/CN107865968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Materials Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201711057517.4A 2012-08-03 2013-08-03 用于治疗溶酶体贮积症的环糊精 Active CN107865968B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679668P 2012-08-03 2012-08-03
US61/679,668 2012-08-03
CN201380052023.0A CN104684585A (zh) 2012-08-03 2013-08-03 用于治疗溶酶体贮积症的环糊精

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380052023.0A Division CN104684585A (zh) 2012-08-03 2013-08-03 用于治疗溶酶体贮积症的环糊精

Publications (2)

Publication Number Publication Date
CN107865968A CN107865968A (zh) 2018-04-03
CN107865968B true CN107865968B (zh) 2021-03-05

Family

ID=49170855

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711057517.4A Active CN107865968B (zh) 2012-08-03 2013-08-03 用于治疗溶酶体贮积症的环糊精
CN201380052023.0A Pending CN104684585A (zh) 2012-08-03 2013-08-03 用于治疗溶酶体贮积症的环糊精

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380052023.0A Pending CN104684585A (zh) 2012-08-03 2013-08-03 用于治疗溶酶体贮积症的环糊精

Country Status (7)

Country Link
US (2) US20150216895A1 (https=)
EP (1) EP2879714B1 (https=)
JP (3) JP2015524444A (https=)
CN (2) CN107865968B (https=)
AU (2) AU2013296170A1 (https=)
CA (1) CA2880880C (https=)
WO (1) WO2014022841A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
WO2015083736A1 (ja) 2013-12-05 2015-06-11 国立大学法人熊本大学 コレステロール蓄積疾患治療薬、およびそのスクリーニング方法
US10413517B2 (en) 2014-06-12 2019-09-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CN107949380B (zh) * 2015-02-11 2021-07-06 西奈山伊坎医学院 用于尼曼-匹克病和其他溶酶体贮积症的npc1的苯磺酰胺上调剂
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
EP3405501B1 (en) * 2016-01-21 2023-11-15 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3515501A1 (en) 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
JPWO2018199287A1 (ja) * 2017-04-28 2020-03-12 国立大学法人京都大学 クリスタリン網膜症の処置および／または予防方法
WO2019067145A1 (en) * 2017-08-28 2019-04-04 Asdera Llc USE OF CYCLODEXTRINS IN DISEASES AND DISORDERS INVOLVING PHOSPHOLIPID DISRUPTION
KR20200107927A (ko) * 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
BR112021008139A2 (pt) 2018-10-29 2021-08-03 Cyclo Therapeutics, Inc. métodos para tratar doença de alzheimer
CN113490691A (zh) 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
JP7264452B2 (ja) * 2019-04-15 2023-04-25 塩水港精糖株式会社 ライソゾーム病の治療または予防のための医薬組成物
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
JP7551339B2 (ja) * 2020-06-04 2024-09-17 株式会社三共 遊技機
JP7551340B2 (ja) * 2020-06-04 2024-09-17 株式会社三共 遊技機
WO2022051631A1 (en) * 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5262404A (en) 1990-02-15 1993-11-16 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
EP0803243B1 (en) 1996-04-24 2003-03-19 Pfizer Inc. Cyclodextrins and phenolic compounds in dental products
FR2767834B1 (fr) 1997-08-29 1999-12-03 Inst Francais Du Petrole Mono et di-derives de cyclodextrines, leurs synthese et purification et leur utilisation en support
AU2001259725A1 (en) 2000-05-15 2001-11-26 The Procter And Gamble Company Compositions comprising cyclodextrin derivatives
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
EP2433650A3 (en) * 2006-06-06 2012-12-19 Tolerrx Inc. Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
WO2010138802A2 (en) * 2009-05-28 2010-12-02 Cornell University Compositions and their use for removing cholesterol
EP2595623B1 (en) * 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
FR3014694B1 (fr) 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Therapeutic Potential of Cyclodextrins in the Treatment of Niemann-Pick Type C Disease;Liu;《Clin Lipidol》;20120601;第7卷(第3期);289-301 *

Also Published As

Publication number Publication date
CN107865968A (zh) 2018-04-03
US20150216895A1 (en) 2015-08-06
JP2020097620A (ja) 2020-06-25
US20180110798A1 (en) 2018-04-26
EP2879714B1 (en) 2021-04-14
CA2880880C (en) 2021-01-26
AU2018202964A1 (en) 2018-05-17
CN104684585A (zh) 2015-06-03
US11020422B2 (en) 2021-06-01
EP2879714A1 (en) 2015-06-10
AU2018202964B2 (en) 2019-08-22
JP6858286B2 (ja) 2021-04-14
CA2880880A1 (en) 2014-02-06
WO2014022841A1 (en) 2014-02-06
JP2015524444A (ja) 2015-08-24
JP2018162277A (ja) 2018-10-18
AU2013296170A1 (en) 2015-03-12
HK1210960A1 (en) 2016-05-13

Similar Documents

Publication Publication Date Title
CN107865968B (zh) 用于治疗溶酶体贮积症的环糊精
Gref et al. Vitamin C–squalene bioconjugate promotes epidermal thickening and collagen production in human skin
Yang et al. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
Zhao et al. Glycophagy: An emerging target in pathology
Adhihetty et al. Effect of denervation on mitochondrially mediated apoptosis in skeletal muscle
Jiang et al. Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury
JP7840031B2 (ja) チロシンキナーゼ阻害剤を用いる組成物および方法
US20130023488A1 (en) Methods and compounds for reducing intracellular lipid storage
Shin et al. Anti-cancer effect of luminacin, a marine microbial extract, in head and neck squamous cell carcinoma progression via autophagic cell death
Chang et al. Elevated autophagy and mitochondrial dysfunction in the Smith–Lemli–Opitz syndrome
Liu et al. Intracellular Zn2+ promotes extracellular matrix remodeling in dexamethasone-treated trabecular meshwork
JP2020500216A (ja) 運動ニューロン疾患の治療のためのガングリオシド代謝阻害剤
Ogita et al. In vivo treatment with the K+ channel blocker 4-aminopyridine protects against kainate-induced neuronal cell death through activation of NMDA receptors in murine hippocampus
Li et al. Hydrogen sulfide ameliorates abdominal aorta coarctation-induced myocardial fibrosis by inhibiting pyroptosis through regulating eukaryotic translation initiation factor 2α phosphorylation and activating PI3K/AKT1 pathway
HK1210960B (en) Cyclodextrin for the treatment of lysosomal storage diseases
Li et al. Role of HMGB1 translocation to neuronal nucleus in rat model with septic brain injury
BRPI0617938A2 (pt) utilização de uma quantidade eficaz de pelo menos uma substáncia modulando a expressão e/ou atividade de lox e de um anticorpo anti-nrage, métodos de utilização e de identificação de pelo menos um princìpio ativo destinado a modular a interação entre lox e nrage e de localização de nrage e processo de preparação de uma composição
Gao et al. Ginsenoside Rb1-enhanced decellularized extracellular matrix hydrogels ameliorates mitochondrial dysfunction and cellular aging in sepsis-induced acute lung injury
WO2005077040A2 (en) Compositions and methods for treating amyotrophic lateral sclerosis (als)
Li et al. Ubiquitin-specific protease 15 reverses the protective effects of sevoflurane on cerebral ischemia-reperfusion injury in mice by deubiquitinating transforming growth factor-βR1
Bragato Generation and characterization of a zebrafish Pompe disease model to test the efficacy of 3-BrPA as a new therapeutic molecule.
Gupta Investigating the Role of Cullin-Ring Ubiquitin Ligase in Regulation
Dinkel Pathological consequences of NPC1 loss in microglia on brain function
EP4507682A1 (en) Iduronidase stabilizers and uses thereof
Niu et al. Mutant huntingtin reduces vesicular zinc level by inhibiting the binding of Sp1 to ZnT3 promoter

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant